| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | CT1.2; MAGE2; MAGEA2A |
| WB Predicted band size | 35 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Synthetic peptide of human MAGEA2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于MAGEA2抗体的3篇参考文献示例(内容为模拟概括，非真实文献)：
1. **"MAGEA2 as a diagnostic biomarker in melanoma: Development of a novel monoclonal antibody"**
- **作者**: Smith A, et al.
- **摘要**: 研究报道了一种新型抗MAGEA2单克隆抗体的开发，验证了其在黑色素瘤组织中的高特异性和敏感性。通过免疫组化分析，该抗体能有效区分肿瘤与正常组织，提示其在临床病理诊断中的潜在应用价值。
2. **"Targeting MAGEA2 with engineered T cells for cancer immunotherapy"**
- **作者**: Johnson R, et al.
- **摘要**: 研究利用抗MAGEA2抗体筛选并改造T细胞受体(TCR)，开发了针对MAGEA2阳性肿瘤的过继性免疫疗法。体外实验显示，该疗法能显著诱导肿瘤细胞凋亡，并在小鼠模型中抑制肿瘤生长。
3. **"MAGEA2 antibody-based detection of circulating tumor cells in lung adenocarcinoma"**
- **作者**: Kumar S, et al.
- **摘要**: 通过抗MAGEA2抗体结合微流控技术，研究建立了一种高灵敏度检测肺腺癌患者循环肿瘤细胞(CTC)的方法，为癌症早期监测和预后评估提供了新工具。
4. **"Structural and functional characterization of MAGEA2-specific antibodies in multiple cancers"**
- **作者**: García-Sánchez M, et al.
- **摘要**: 通过晶体学分析MAGEA2抗原-抗体复合物，揭示了抗体结合表位的关键区域，并在乳腺癌、卵巢癌等多种癌症模型中验证了其靶向治疗的潜力。
(注：以上文献名为模拟生成，实际引用请通过PubMed/Google Scholar等平台检索真实研究。)
The MAGE-A2 antibody targets the melanoma-associated antigen A2 (MAGEA2), a member of the MAGE (melanoma antigen gene) family. MAGEA2 is part of the MAGE-A subfamily, which consists of cancer-testis antigens (CTAs) primarily expressed in germ cells (e.g., testes, placenta) but silenced in most healthy somatic tissues. Aberrant MAGEA2 expression is observed in various cancers, including melanoma, lung, liver, and head/neck carcinomas, making it a tumor-specific biomarker and therapeutic target. Its restricted normal tissue expression reduces off-target risks, enhancing its appeal for immunotherapy.
MAGEA2 antibodies are critical tools in research and diagnostics, used to detect protein expression via techniques like immunohistochemistry (IHC) or Western blotting. Clinically, MAGEA2 is explored for immunotherapeutic strategies, such as cancer vaccines, adoptive T-cell therapies, or antibody-drug conjugates (ADCs), aiming to direct immune responses or cytotoxic agents against MAGEA2-positive tumor cells. However, challenges persist, including heterogeneous MAGEA2 expression within tumors, potential immune evasion mechanisms, and safety concerns if expression occurs in immune-privileged sites. Despite these hurdles, MAGEA2 remains a promising candidate for precision oncology, with ongoing studies optimizing its targeting efficacy and specificity.
×
